News – Page 634 – Endpoints News

Troubled Voyager’s gene therapy relaunch gets a boost with $630M Pfizer deal

4 years ago

Unfazed by OS flop, Zai Lab eyes imminent China filing for MacroGenics' HER2 drug

4 years ago

FDA center directors on lessons from the EUA pathway: Flexibility serves us well

4 years ago

After a brief stint in the top cancer research spot at Gilead, Valeria Fantin jumps over to Sanofi

4 years ago

Ex-FDA officials ask SCOTUS to take up J&J talc case; Annovis shows data from PhII Parkinson's trial

4 years ago

Medicxi co-founder David Grainger gets his other foot in Centessa's door as chief innovation officer

4 years ago

A year into SPAC merger, Gemini restructures pipeline with 20% of staff, leadership on the chopping block

4 years ago

iOmx refuels with $75M+ on its search for immune checkpoint targets on tumor cells

4 years ago

GlaxoSmithKline abandoning iconic US HQ space in a shift inspired by the new normal

4 years ago

Vedanta brings home a win for lead microbiome program, passing a PhII test and clinching BARDA investment

4 years ago

Covid-19 roundup: Scientists pull pre-print with inflated incidence of myocarditis post mRNA vaccine; AstraZeneca ...

4 years ago

A month after a manufacturing hiccup led to a CRL, CorMedix CEO will retire

4 years ago

Feds accuse AstraZeneca of underpaying 318 female and Hispanic employees

4 years ago

Longtime NIH director Francis Collins resigns to make room for 'new vision'

4 years ago

New small molecule player with roots in David Liu's lab collects another $78M to fuel search for exosites

4 years ago

Gang of 7: Boehringer joins group of companies targeted over drug discount program

4 years ago

Estate of Henrietta Lacks sues Thermo Fisher over the improper sale of her immortal cells

4 years ago

AstraZeneca's Enhertu gets BTD for breast cancer; Centessa nabs $300M loan

4 years ago

Has Selecta found a way around gene therapy's delivery problem? Takeda puts down $1B-plus to find out

4 years ago

Teva temporarily padlocks a plant after FDA cites it for contamination

4 years ago

BioMarin recruits Vertex's translational chief to head up clinical trial ops

4 years ago

Enanta culls internal NASH work, betting on an out-licensing strategy in the disaster-strewn field

4 years ago

Canada's Xenon touts out-of-the-blue win for its daily epilepsy pill, sending investors into a frenzy

4 years ago

J&J signs on Xencor for a $100M licensing deal targeting CD20, looking to press its advantage in bispecifics

4 years ago

First page Previous page 631 632 633634635 636 637 Next page Last page